If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.Doxylamine: May enhance the CNS depressant effect of CNS Depressants.

Not for OTC use in children <2 years of age.• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Available for Android and iOS devices. )Tableau des médicaments d'ordonnance contre l'eczémaOptions thérapeutiques pour la mycose de l'ongle des orteils When using for nausea and vomiting of pregnancy, administer dose (diluted in 50 mL of normal saline) over 20 minutes (Arsenault 2002).Rectal suppository [Canadian product]: To prevent motion sickness, nausea/vomiting, or vertigo, administer 30 minutes prior to event.Tablets may be taken with food or water. Quant aux suppositoires, la dose pour ce groupe d'âge est de 25 à 50 mg toutes les 8 à 12 heures selon le besoin. Le dimenhydrinate appartient au groupe de médicaments appelés antiémétiques. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. These agents should only be combined if alternative treatment options are inadequate. These agents should only be combined if alternative treatment options are inadequate.

Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Pour les enfants de 8 à 12 ans, la dose de dimenhydrinate (liquide ou comprimé) est de 25 à 50 mg toutes les 6 à 8 heures selon le besoin, sans dépasser 150 mg par période de 24 heures. Dimenhydrinate, marketed as Draminate, Dramamine and Gravol among others, is an over-the-counter drug used to treat motion sickness and nausea.

See manufacturer's labeling.• Abuse/withdrawal: Has abuse potential due to its hallucinogenic and euphoric effects; discontinuation after chronic abuse may lead to withdrawal symptoms (eg, lethargy, agitation, hostility, hallucinations, confusion, aggression, nausea/vomiting).Dimenhydrinate crosses the placenta. If combined, limit the dosages and duration of each drug.Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Ce médicament est offert sous forme d'injection dosée à 10 mg par mL et 50 mg par mL. Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics.

Quant aux suppositoires, la dose pour ce groupe d'âge est de 12,5 à 25 mg. Ne pas donner plus d'une dose en suppositoire, sauf sur recommandation de votre médecin. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended.Dronabinol: May enhance the CNS depressant effect of CNS Depressants.Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.

Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. See manufacturer's labeling.• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant.

Management: Consider alternatives to combined use.

No such dose change is recommended for women.

Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation).